Could a daily cannabinoid pill shield Athletes' brains from concussion?
NCT ID NCT07715864
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether a daily broad-spectrum cannabinoid capsule can protect the brain and speed recovery from concussion in healthy male athletes who play contact sports. Participants take either the active capsule or a placebo twice daily, and researchers measure brain blood flow, inflammation markers, and concussion rates. The goal is to see if this natural compound can reduce injury and support brain health during high-impact competition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a broad-spectrum cannabinoid formulation in a gel capsule
- What this could lead to
- If it works, this could point toward a daily supplement that reduces concussion risk and speeds brain recovery in contact-sport athletes.
- What could go wrong
- This is a small early-phase trial in healthy male athletes only, so results may not apply to others. The cannabinoid formulation may cause side effects or fail to show a protective effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 35 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy male adults between 19-35 years of age that compete in contact sport athletics. * Participants with no known cerebrovascular or cardiovascular complications. * Participants will not be habitual recreational users of cannabis (i.e., \<1 day/week) or tobacco users. * Participants that agree not use any other cannabis or tobacco products while enrolled in the study. * Participants willing to provide a list of any prescription medications they are taking. * Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests. * Participants who are capable of giving signed informed consent. Exclusion Criteria: * Female. * Must not travel to the USA during study period; USA laws do not permit cross border with cannabis products. * Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2-month period without use of cannabis-based therapy prior to enrollment in the study). * Participants with any level of cannabis in their blood samples when sampled at the commencement of the study will be excluded. * Participants that are being medically supervised for anxiety, depression, Post Traumatic Stress Disorder (PTSD), mood disorder, psychotic disorders or any cerebrovascular and cardiovascular complications. * Participants who are taking prescription medications such as psychotropic medications with serotonergic activity, including Selective Serotonin Reuptake Inhibitors (i.e. Fluoxetine), Tricyclic Antidepressants (i.e. Elavil, Nortriptyline) and Atypical Neuroleptics (i.e. Risperidone, Seroquel). * Initiation or dosage change of oral or injected steroids within 3 months. * Allergy or known intolerance to any of the compounds within the study preparation. * Unable to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, and functional motor skills laboratory tests. * Inability of study participants to attend assessments on a regular basis at the pre-determined times, or failure to take the drug daily. * Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator). * If they already have a concussion at the time of starting the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Regina
RECRUITINGRegina, Saskatchewan, S4S-0A2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The effects of external nasal dilator strips on sleep and cardiovascular health
- A pharmacokinetic study of NTI164 in healthy adult volunteers
- Genetic determinants of Exercise-Induced muscle damage (POLYGENDOMUS) / déterminants génétiques des dommages musculaires induits par l'Exercice (POLYGENDOMUS)
- Can a simple injection timing reduce bleeding after skin cancer surgery?
- Can Land-Based teachings shape psychedelic therapy training?
- Can a new oral drug pass early safety tests?